Regulatory Affairs Professionals Society Steps Up Presence in Europe
The Regulatory Affairs Professionals Society (RAPS) is stepping up its presence in Europe and expanding its European team in response to growing membership demand from those involved with the regulation of healthcare and related products. In the last 12 months, the largest global organization for regulatory professionals in the healthcare, medical device, biologic and pharmaceutical sectors has reportedly seen its European member base grow by approximately 19 per cent to more than 1,500 members across 29 countries. RAPS plans to invest more than €2 million over three years implementing a strategic growth plan in Europe that includes launching new events and resources to serve the needs of regulatory professionals in the region. The investment program includes a substantial increase in staff resources for European members and a series of European events including a RAPS Roadshow: ‘Examining the New European Medical Device Regulations’ on 4 May in Munich and a workshop ‘EU Regulatory Essentials, Medical Device and In Vitro Diagnostics: Transitioning from Current Directives to New Regulations’ on July 4-5 in Brussels.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
FDA Approves Celltrion’s Biosimilars Stoboclo and Osenvelt
March 4th 2025Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors.
